Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

GSK Validates High Throughput Format of Gentronix BlueScreen® Assay

Published: Thursday, April 25, 2013
Last Updated: Thursday, April 25, 2013
Bookmark and Share
BlueScreen-384 provides robust, reproducible, and consistent results.

Gentronix has announced the findings of new research published by GlaxoSmithKline (GSK) on the miniaturization and automation of BlueScreen™ HC; a proprietary assay developed by Gentronix for high throughput genotoxicity testing.

Presented in the peer-reviewed Journal of Biomolecular Screening, the study demonstrates that BlueScreen-384 can reduce the need for costly and time-consuming analogue testing in more traditional genotoxicity methods such as the Ames test.

GSK researchers scaled down the assay for use with 384-microwell plates and available reader technologies in high throughput applications and showed that BlueScreen-384 provided robust, reproducible, and consistent results, supporting its use as a routine genotoxicity screening assay.

Importantly, the research also demonstrated how the exploration of structure-activity relationships around a genotoxic lead molecule could be used to identify non-genotoxic analogues.

BlueScreen HC is an innovative assay from Gentronix, which uses genetically modified, human-derived cells containing the GADD45a gene coupled to Gaussia luciferase to detect the genotoxic effects of compounds with high specificity and sensitivity.

Commenting on the publication, Dr Steve Beasley, Commercial Director at Gentronix, said: “The GSK paper provides valuable insights and independent verification for the scalability of our proven BlueScreen HC technology. Additionally, the successful miniaturization of BlueScreen-384 further opens up possibilities for high throughput genotoxicity measurement across a wide range of industries.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gentronix Awarded Grant of £147,552 by MRC and Technology Strategy Board
Company awarded grant from the Biomedical Catalyst programme for an epigenetic based screening assay feasibility study.
Thursday, December 20, 2012
Improved In Vitro Genotoxicity Testing to Reduce Animal Testing
In conjunction with the University of Manchester, Gentronix has been granted a research award of £133,024.
Thursday, August 10, 2006
Gentronix Secures R&D Award
The two-year grant will provide Gentronix with two scientists, cell culture facilities, and supporting laboratory instrumentation at its Manchester Incubator Core Technology Facility premises.
Tuesday, April 11, 2006
Scientific News
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Potential Target for Treatment of Autism
Grant of $2.4 million will support further research.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos